Both in Pharmaceuticals
Ultragenyx Pharmaceutical vs AnaptysBio
Over the past year RARE returned −52.3% and ANAB returned +51.2%; their daily moves had a correlation of 0.08.
RARE −52.3% ANAB +51.2%Growth of $1, one year, split-adjusted
| Metric | RARE | ANAB |
|---|---|---|
| Price | $15.13 | $48.16 |
| Market cap | $1.49B | $1.44B |
| Today | +1.51% | +3.19% |
| 1 month | +17.4% | −11.3% |
| 6 months | −38.3% | −28.0% |
| Year to date | −34.2% | −0.7% |
| 1 year | −52.3% | +51.2% |
| Revenue growth (YoY) | +28.1% | −8.0% |
| Gross margin | 84.1% | 100.0% |
| Net margin | −43.0% | −206.9% |
| P/E (TTM) | — | — |
| Price / sales | 2.1× | 6.2× |
| Net cash | $292.0M | $286.5M |
| Dividend yield | — | — |
| Volatility (60d) | 127.6% | 36.0% |
| Short % of float | 21.8% | 30.0% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).